Dentsply Sirona initiates strategic alternatives review for Wellspect Healthcare

DENTSPLY SIRONA (XRAY) has initiated a process to evaluate strategic alternatives for its Wellspect Healthcare business. Wellspect is a leading provider of bladder and bowel management care products with an over 40-year history. Through its comprehensive portfolio of products and accessories from trusted brands like LoFric and Navina, Wellspect has delivered improved organic sales growth in recent years, including mid-to-high single digit growth for 2023 and through the first three quarters of 2024. The business is well-positioned in the large and growing continence care space, which has an estimated $2 billion total addressable market. “We have initiated a review of strategic alternatives for Wellspect as we believe that taking this step now enables us to unlock significant potential value for all our stakeholders,” said Simon Campion, CEO. “As part of our transformation strategy over the last few years, we invested in strengthening Wellspect’s foundation and positioning the business for the future by prioritizing product innovation, profitable revenue growth and capacity expansion to meet anticipated demand growth. Importantly, we developed a strong product pipeline with potential opportunities to access significant untapped markets in Wellspect’s core business and other adjacencies, and we have seen early indications that this added focus has led to improved financial performance. We look forward to determining an outcome for Wellspect that supports the business’ enhanced growth trajectory and success while also enabling Dentsply Sirona to focus our resources and attention on our dental business.”